Alexion Pharms logo

Alexion Pharms

Stock
Stock
ISIN: US0153511094
US0153511094

Price

Price

CHART BY

Frequently asked questions

What is the Earnings Per Share (EPS) for Alexion Pharms?

Alexion Pharms's Earnings Per Share (EPS) over the trailing twelve months (TTM) is 3.057. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for Alexion Pharms's stock?

Currently, 1 analysts cover Alexion Pharms's stock, with a consensus target price of $175.00. Analyst ratings provide insights into the stock's expected performance.

What is Alexion Pharms's revenue over the trailing twelve months?

Over the trailing twelve months, Alexion Pharms reported a revenue of $6.28B.

What is the EBITDA for Alexion Pharms?

Alexion Pharms's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $3.28B. EBITDA measures the company's overall financial performance.

What is the free cash flow of Alexion Pharms?

Alexion Pharms has a free cash flow of $2.98B. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

How many employees does Alexion Pharms have, and what sector and industry does it belong to?

Alexion Pharms employs approximately 3,837 people. It operates in the Health Care sector, specifically within the Pharmaceuticals: Major industry.

Financials

EPS (TTM) 
3.057
Revenue (TTM) 
$6.28B
EBITDA (TTM) 
$3.28B
Free Cashflow (TTM) 
$2.98B

Analyst Ratings

The price target is $175.00 and the stock is covered by 1 analysts.

Buy

0

Hold

1

Sell

0

Information

Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA.

Employees
3,837
Industries
Pharmaceuticals: Major
Sector
Health Care

Identifier

ISIN
US0153511094

Knockouts

Join the conversation